Liposomes used for the enzymatic degradation of ingested ethanol

By encapsulating enzymes with liposomes and polymer vesicles and utilizing oxygen as a cofactor, ethanol is degraded in the stomach. This solves the problem of instability of enzyme preparations in acidic environments in existing technologies, enabling rapid degradation of ethanol in the stomach and improving the safety and health of drinking.

CN123124966APending Publication Date: 2026-11-17ACRES CORP
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202580029205.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-08
Filing Date
2025-03-07
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies struggle to provide a simple and self-administered enzyme preparation that can effectively degrade ethanol in the stomach, is suitable for processing alcoholic beverages after ingestion before they are absorbed into the bloodstream, especially for people with alcohol intolerance, and needs to remain stable in acidic and proteolytic environments.

Method used

The enzyme is encapsulated in liposomes and/or polymer vesicles, and oxygen is used as a cofactor to assist the enzyme in degrading ethanol. The enzyme is independent of NAD+ and NADH, and the liposomes and polymer vesicles are stable at acidic pH, with a particle size greater than 100 nm and an enzyme concentration greater than 100 U/ml, enabling it to rapidly degrade ethanol in the stomach.

Benefits of technology

It achieves effective degradation of ethanol in the stomach, reducing the negative effects of ethanol on the human body. It is suitable for pre-absorption processing of alcoholic beverages after ingestion, improving the safety and health of drinking, especially protecting people with alcohol intolerance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124966A_ABST
    Figure CN123124966A_ABST
Patent Text Reader

Abstract

The present invention relates to a composition comprising liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol, wherein the enzyme capable of degrading ethanol (in ethanol decomposition) is assisted by a cofactor capable of diffusing across the cell membrane of the liposomes and / or polymer vesicles.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of enzyme technology and to liposome systems and products for the degradation of ethanol. Specifically, this invention relates to liposomes and polymeric vesicles comprising enzymes for the degradation of ethanol in the human stomach. Background Technology

[0002] The global alcoholic beverage market is projected to continue its significant growth in the future. Demand is strongly driven by a substantial increase in the consumption and culture of alcoholic beverages among millennials worldwide.

[0003] Ethanol is an alcohol compound found in most alcoholic beverages. After ingestion, a small portion of ethanol may be absorbed into the bloodstream as the body passes through.

[0004] Once in the bloodstream, ethanol has a variety of effects on the human body. These effects are mainly described as negative in the literature and may include inhibitory effects on the brain, uncontrolled behavior, and increased risk of cardiovascular disease and cancer.

[0005] Despite these negative effects, alcohol / ethanol is still enjoyed by many people and consumed worldwide. It is difficult to give an accurate estimate of ethanol absorption and metabolism because it varies depending on genetics, diet, condition, and many other factors. Peak blood alcohol concentration is typically reached 30 minutes after ingestion.

[0006] Ethanol absorption occurs throughout the gastrointestinal tract, but it is primarily absorbed in the small intestine, especially in the duodenum and jejunum, due to their large surface area (villi). Ethanol is mainly degraded in the liver, and the rate of degradation depends on factors such as the amount of ethanol ingested.

[0007] Ethanol is toxic and causes approximately 2.8% of all deaths worldwide. Ethanol is even more dangerous for people with ALDH2 deficiency (i.e., alcohol intolerance). Alcohol intolerance is a genetic condition, most common in East Asia (30-50% of the population). The condition is caused by gene mutations that impair the metabolism of acetaldehyde, a byproduct of ethanol degradation. This leads to a variety of symptoms, such as facial flushing, rapid heartbeat, nausea, and an increased risk of cancer.

[0008] Therefore, many people have difficulty drinking alcoholic beverages, either because they experience alcohol flushing or because they simply want to avoid the effects of alcohol while drinking.

[0009] One option is to turn to non-alcoholic beverages, but these may not be available at the places and times where alcoholic beverages are consumed. Furthermore, non-alcoholic beverages may taste different from their alcoholic counterparts.

[0010] Another proposed option is to use enzymes to degrade ethanol and optionally acetaldehyde. Many products are currently attempting to address this problem. However, the market is quite fragmented. Some of these products are based on enzyme solutions, and these enzyme-based solutions have not yet penetrated the market.

[0011] Others have addressed the liposome encapsulation of alcohol dehydrogenase (ADH). US 2021 / 0213107 describes a microparticle composition containing, for example, ADH to degrade ethanol. This composition is intended for delivery into the bloodstream for the degradation of ethanol in the blood. Furthermore, Yoshimoto et al. (2008) disclosed the encapsulation of ADH in liposomes.

[0012] There is still a need for simpler, self-administered products that could potentially make enjoying alcoholic beverages safer and healthier. Summary of the Invention

[0013] The object of this invention is to provide compositions that make the enjoyment of alcoholic beverages safer and healthier, suitable for both those who tolerate and those who are intolerant to alcohol. A further object of this invention is to provide compositions that can be administered individually without the need for medical personnel. A further object of this invention is that the compositions can withstand the harsh acidic and proteolytic environment of the stomach after ingestion. An even further object of this invention is that the compositions, after ingestion, can function and exert their activity in the stomach before the ethanol reaches the small intestine and is absorbed into the bloodstream.

[0014] Therefore, one aspect of the present invention relates to a composition comprising liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol, wherein the enzyme capable of degrading ethanol (in ethanol decomposition) is assisted by a cofactor capable of diffusing across the cell membrane of the liposomes and / or polymer vesicles.

[0015] A further aspect of the invention relates to a composition comprising liposomes and / or polymeric vesicles, wherein the liposomes and / or polymeric vesicles encapsulate an enzyme capable of degrading ethanol, wherein the enzyme capable of degrading ethanol is NAD-independent. + And / or NADH.

[0016] Another aspect of the invention relates to a composition comprising liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol, wherein the enzyme capable of degrading ethanol uses oxygen as the final electron acceptor.

[0017] A further aspect of the invention relates to a composition comprising liposomes and / or polymeric vesicles, wherein the liposomes and / or polymeric vesicles encapsulate an enzyme capable of degrading ethanol, and wherein the liposomes and / or polymeric vesicles do not encapsulate NAD. + Or NADH.

[0018] A further aspect of the invention relates to a composition comprising liposomes and / or polymeric vesicles, the liposomes and / or polymeric vesicles encapsulating an enzyme capable of degrading ethanol, wherein the liposomes and / or polymeric vesicles meet at least one of the following criteria: i. The composition in which the amount of enzyme is higher than 100 U / ml; ii. Wherein the liposomes and / or polymer vesicles contain a particle size of at least 100 nm; iii. The composition is capable of degrading ethanol in the range of 50-5000 mM per hour; iv. Wherein the liposomes and / or polymeric vesicles are stable at acidic pH, for example at pH 5.5 or lower; and / or v. Where the pH inside the liposomes and / or polymer vesicles is higher than pH 6.0.

[0019] Another aspect of the invention relates to a unit dose comprising the composition according to the invention, wherein the unit dose comprises an enzyme of 50 U / unit dose or higher, the enzyme being encapsulated in liposomes and / or polymer vesicles.

[0020] Another aspect of the invention relates to a composition for degrading ethanol in the stomach, such as an ingestible composition comprising liposomes and / or polymeric vesicles encapsulating an enzyme that degrades ethanol, wherein the liposomes and / or polymeric vesicles are stable at an acidic pH.

[0021] Another aspect of the present invention relates to a method for preparing a composition (e.g., an ingestible composition) for degrading ethanol in the stomach, the composition comprising liposomes and / or polymeric vesicles encapsulating an enzyme that degrades ethanol, said method comprising the following steps: a) Dissolve phospholipids in an organic solvent. b) Hydrated phospholipids in an aqueous solution of at least one enzyme that degrades ethanol. c) Freeze the hydrated lipids in liquid nitrogen. d) Thaw in an aqueous solution at 20°C and freeze in liquid nitrogen, repeating at least 3 cycles. e) Optionally, extrusion may be performed to obtain more uniform sizes, thereby obtaining the liposomes and / or polymer vesicles.

[0022] A further aspect of the invention relates to the use of compositions according to the invention (e.g., ingestible compositions) for the degradation of ingested ethanol in the stomach.

[0023] A further aspect of the invention relates to a kit comprising a composition according to the invention and an instruction manual according to the invention.

[0024] Another aspect of the invention relates to compositions according to the invention for treating, preventing, or reducing alcohol flushing. Attached Figure Description

[0025] Figure 1 The activity of alcohol dehydrogenase (ADH) encapsulated in liposomes is shown. Bottom curve: Enzyme, pH 4. Middle curve: Liposomes containing the enzyme but without detergent, pH 4. Top curve: Liposomes containing both enzyme and detergent, pH 4.

[0026] Figure 2 The activity of alcohol oxidase (AOX) encapsulated in liposomes was demonstrated. The figure shows Pichia pastoris encapsulated in liposomes. Pichia pastoris Time-dependent oxidation of 50 mM ethanol to H2O2 by alcohol oxidase (pAOX) in phosphate buffer at pH 3 (the line above).

[0027] Figure 3 The in vitro (free) ADH and aldehyde dehydrogenase (ALDH) activities of lipids are displayed. The x-axis shows time (seconds), while the y-axis shows absorbance measured at 340 nm. Absorbance corresponds to NADH production. Samples were measured in triplicate per minute for 5 minutes. Different enzyme samples were dissolved in Tris-HCl buffer at pH 8.5 containing NAD. + And ethanol. Each sample shows a linear trend line. This clearly demonstrates that ALDH can break down acetaldehyde into acetic acid.

[0028] Figure 4 The stability of the enzymes after dissolution in acidic buffer for different time periods is shown. The x-axis shows how many minutes the enzyme was treated at pH 2. The y-axis shows the retention activity (%) relative to 0 minutes at pH 2. After 30 minutes at pH 2, V2 retained approximately 100% activity, while the native enzyme retained 0.2%. The membrane of V2 liposomes consisted of 30% cholesterol and 70% POPC, while the membrane of V1 consisted of POPC only. The enzymes were ADH-containing in all cases. The native enzyme (gray) was not encapsulated and retained nearly 0% activity after only half a minute at pH 2. ADH-containing V1 and V2 liposomes still showed activity after 60 minutes at pH 2.

[0029] Figure 5 The study demonstrated NADH peroxidase activity in two samples, both containing ALDH, AOX, 1% ethanol, 40 mM phosphate buffer (pH 7.5), and a limited amount of NAD. + .

[0030] Figure 6 The results of testing liposomes containing an enzyme system consisting of AOX, ALDH, and NADH peroxidases (NP) at pH 3 are shown.

[0031] Figure 7 The results of ethanol degradation under unencapsulated conditions at pH 7.5 are shown by an enzyme system consisting of AOX, ALDH, and NADH peroxidases (NP).

[0032] Figure 8 Enzymatic ethanol degradation in a gastric model was demonstrated.

[0033] Figure 9 Ethanol degradation of liposomes loaded with AOX, catalase (CAT), and a combination of AOX and CAT (MIX) was demonstrated.

[0034] Figure 10 Ethanol degradation of AOX-loaded liposomes was shown, with oxygen (O2) acting as a cofactor.

[0035] The present invention will now be described in more detail below. Detailed Implementation

[0036] The inventors of this invention have surprisingly discovered a composition that enables people with alcohol intolerance to drink alcohol with fewer or no symptoms.

[0037] This is facilitated by the composition of the present invention, which can break down ethanol in the stomach before it is absorbed into the bloodstream and thus distributed throughout the body.

[0038] Therefore, the composition of the present invention can transfer ethanol metabolism from the liver to the stomach.

[0039] In this way, alcoholic beverages can be enjoyed as if they were virtually alcohol-free. This is relevant to people who experience alcohol flushing and those who wish to avoid the effects of alcohol when drinking.

[0040] The compositions according to the present invention can also potentially make the enjoyment of alcoholic beverages safer and healthier.

[0041] Surprisingly, it has been found that despite the harsh environment of acidity and proteolytic activity in the stomach, the ingestible composition of the present invention enables the efficient degradation of ethanol.

[0042] The terms "ethanol degradation" and "degradation of ethanol" as used herein are intended to refer to any chemical reaction that converts ethanol into another compound. Non-limiting examples of ethanol degradation include the conversion of ethanol into acetaldehyde, acetic acid, carbon dioxide, etc.

[0043] Therefore, the liposomes and / or polymeric vesicles present in the compositions according to the invention can preferably be configured to perform ethanol degradation primarily in the human stomach.

[0044] Unless otherwise stated, the present invention will be practiced using conventional techniques of enzymology and liposome technology within the scope of the art. Such techniques are well explained in the literature. See, for example, the references cited herein.

[0045] Therefore, a preferred embodiment of the present invention relates to a composition comprising liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol, wherein the enzyme capable of degrading ethanol (in ethanol decomposition) is assisted by a cofactor capable of diffusing across the cell membrane of the liposomes and / or polymer vesicles.

[0046] In the context of this invention, cofactors can assist enzymes in breaking down and / or degrading ethanol in the stomach by catalyzing enzyme reactions, such as by participating in redox reactions or helping substrate binding.

[0047] In one embodiment of the invention, the enzyme capable of degrading ethanol according to the invention is independent of NAD. + And / or NADH.

[0048] Preferably, the cofactor according to the present invention may be oxygen (O2).

[0049] When oxygen (O2) is used as a cofactor in this invention, oxygen (O2) can be used as the final electron acceptor.

[0050] Although oxygen (O2) itself is not typically considered a classic ion-based cofactor (it is usually a metal ion-based cofactor), oxygen (O2) can serve as a molecule required for enzyme activity, and in some cases, it can interact with metal cofactors such as Fe. 2+ Cu 2+ They may work together with heme groups to help promote redox reactions involving oxygen (O2).

[0051] Oxygen (O2) can generally be considered as a substrate or cosubstrate, rather than a traditional cofactor. However, it can function as a cofactor, and therefore oxygen (O2) is considered as a cofactor according to the present invention.

[0052] When oxygen (O2) is used as a cofactor or cosubstrate, it assists enzymes (such as oxidases) in breaking down ethanol by using oxygen (O2) as an electron acceptor (such as cytochrome c oxidase in the electron transport chain).

[0053] A preferred embodiment of the present invention relates to a composition comprising liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol, wherein the enzyme capable of degrading ethanol is NAD-independent. + And / or NADH.

[0054] A further preferred embodiment of the invention relates to a composition comprising liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol, wherein the enzyme capable of degrading ethanol uses oxygen as the final electron acceptor.

[0055] This invention may relate to a composition comprising liposomes and / or polymeric vesicles, wherein the liposomes and / or polymeric vesicles encapsulate an enzyme capable of degrading ethanol, and wherein the liposomes and / or polymeric vesicles do not encapsulate NAD. + Or NADH.

[0056] Therefore, a preferred embodiment of the present invention relates to a composition comprising liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol, wherein the liposomes and / or polymer vesicles meet at least one of the following criteria: i. The composition in which the amount of enzyme is higher than 100 U / ml; ii. Wherein the liposomes and / or polymer vesicles contain a particle size of at least 100 nm; iii. The composition is capable of degrading ethanol in the range of 50-5000 mM per hour, preferably per unit dose of the composition; iv. Wherein the liposomes and / or polymeric vesicles are stable at acidic pH, for example at pH 5.5 or lower; and / or v. Where the pH inside the liposomes and / or polymer vesicles is higher than pH 6.0.

[0057] Another preferred embodiment of the invention relates to a composition comprising liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol, wherein the amount of enzyme is greater than 100 U / mL of the composition.

[0058] Another preferred embodiment of the invention relates to a composition comprising liposomes and / or polymer vesicles, the liposomes and / or polymer vesicles encapsulating an enzyme capable of degrading ethanol, wherein the liposomes and / or polymer vesicles contain a particle size of at least 100 nm.

[0059] A further preferred embodiment of the invention relates to a composition comprising liposomes and / or polymer vesicles, the liposomes and / or polymer vesicles encapsulating an enzyme capable of degrading ethanol, wherein the composition is capable of degrading ethanol in the range of 50-5000 mM per hour, preferably per unit dose of the composition.

[0060] Preferably, at least two of the criteria can be satisfied, even more preferably at least three of the criteria, even more preferably at least four of the criteria, and even more preferably all five criteria can be satisfied.

[0061] In one embodiment of the invention, criterion (i) may be satisfied.

[0062] In a further embodiment of the invention, standard (ii) may be satisfied.

[0063] In another embodiment of the invention, a combination of standard (i) and standard (ii) or standard (iii) may be satisfied. Preferably, a combination of standard (i) and standard (ii) and standard (iii) may be satisfied.

[0064] In an even further embodiment of the invention, a combination of standard (i) and standard (ii) may be satisfied.

[0065] In another embodiment of the invention, a combination of standard (ii) and standard (iii) may be satisfied.

[0066] The liposomes and / or polymer vesicles according to the present invention may preferably comprise monolayer liposomes and / or polymer vesicles.

[0067] Liposomes are typically small vesicles formed from lipids such as cholesterol and / or phospholipids. They may consist of at least one lipid membrane and a hydrophilic core. They have monolayer or bilayer membranes and their size typically varies between 20 and 2000 nanometers, but can also be larger. Liposomes and their preparation methods are further described, for example, by Akbarzadeh et al. (2013).

[0068] The liposomes according to the invention may involve small vesicles that can be formed from lipids such as cholesterol or phospholipids. The liposomes according to the invention may comprise a single or double membrane. Their size may vary, but are typically measured to be 20-5000 nanometers (nm).

[0069] Polymer vesicles are also very similar to liposomes. However, despite their similar amphiphilicity, liposomes and polymer vesicles exhibit important physical differences. Most notably, the molecular weight of the constituent compounds varies, with liposomes ranging from 100–1000 g / mol to polymer vesicles from 1000–10000 g / mol. Phospholipids are commonly used in liposomes, while amphiphilic block copolymers are typically used in polymer vesicles. Another difference may be the membrane thickness of liposomes, which is 3–5 nm, compared to 5–50 nm for polymer vesicles.

[0070] Small molecules such as ethanol, acetaldehyde, and acetic acid can readily diffuse across the cell membranes of the liposomes and / or polymer vesicles according to the invention. Furthermore, due to the hydrophobicity of lipids, the lipid membrane does not allow protons to pass through. It is not desirable to be bound by theory; these principles are believed to be the basis for the operation of the liposome compositions of the present invention. Conventional liposomes are not necessarily stable in the stomach. They are susceptible to the combined effects of gastric acid, bile salts, and pancreatic lipases. This leads to a reduction in the number of intact liposomes.

[0071] The liposomes and / or polymer vesicles according to the present invention can be spherical, and therefore the particle size of the liposomes and / or polymer vesicles can be determined as the diameter of the spherical liposomes and / or polymer vesicles.

[0072] Preferably, the liposomes and / or polymer vesicles according to the invention comprise particle sizes greater than 100 nm, for example greater than 200 nm, for example greater than 300 nm, for example greater than 400 nm, for example greater than 500 nm, for example greater than 600 nm, for example greater than 700 nm, for example greater than 800 nm, for example greater than 900 nm, for example greater than 1000 nm, for example greater than 1200 nm, for example greater than 1500 nm, for example greater than 2000 nm, for example greater than 2500 nm, for example greater than 3000 nm, for example greater than 3500 nm, for example greater than 4000 nm, for example greater than 4500 nm, for example greater than 5000 nm, for example in the range of 100-5000 nm, for example in the range of 200-4500 nm, for example in the range of 300-4000 nm, for example in the range of 500-3500 nm. Within the nm range, for example, the 800-3000 nm range, the 900-2500 nm range, the 1000-2000 nm range, and the 1200-1500 nm range.

[0073] Preferably, the liposomes and / or polymeric vesicles may contain an enzyme concentration or amount of 50 U / ml or higher, such as 75 U / ml or higher, 100 U / ml or higher, 125 U / ml or higher, 150 U / ml or higher, 175 U / ml or higher, 200 U / ml or higher, 250 U / ml or higher, 300 U / ml or higher, 350 U / ml or higher, 400 U / ml or higher, 500 U / ml or higher, 600 U / ml or higher, 700 U / ml or higher, 800 U / ml or higher, 900 U / ml or higher, 1500 U / ml or higher, 2000 U / ml or higher, 3000 U / ml or higher, or 4000 U / ml or higher. U / ml composition or higher, such as 5000 U / ml composition or higher, such as in the range of 50-5000 U / ml composition, such as in the range of 75-4000 U / ml composition, such as in the range of 100-3000 U / ml composition, such as in the range of 125-2000 U / ml composition, such as in the range of 150-1500 U / ml composition, such as in the range of 175-1000 U / ml composition, such as in the range of 200-800 U / ml composition, such as in the range of 250-600 U / ml composition, such as in the range of 300-400 U / ml composition.

[0074] Alternatively, liposomes and / or polymeric vesicles may contain enzyme concentrations or amounts, for example, in the range of 50-5000 U / ml, for example, in the range of 125-4000 U / ml, for example, in the range of 250-3500 U / ml, for example, in the range of 500-3000 U / ml, for example, in the range of 1000-2500 U / ml, for example, in the range of 1500-2000 U / ml.

[0075] The term U / ml may refer to the concentration or amount of enzyme (ethanol-degrading enzyme or enzyme capable of degrading ethanol, which are used interchangeably) relative to the amount of the composition.

[0076] Unless otherwise specified, the term "enzyme" may preferably refer to an ethanol-degrading enzyme for degrading ethanol or the entire enzyme complex of an enzyme capable of degrading ethanol.

[0077] In the context of this invention, the term "U" or "unit" is used interchangeably and can be calculated based on the ability of one unit to oxidize 1.0 μmol of ethanol to acetaldehyde per minute at 25°C at the optimal pH (preferably pH 7.5) of the enzyme in question.

[0078] In one embodiment of the invention, the liposomes and / or polymer vesicles contain a particle size greater than 100 nm, and the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol, wherein the liposomes and / or polymer vesicles provide an enzyme concentration or amount greater than 100 U / ml of the composition.

[0079] In a further embodiment of the invention, when the protein is an alcohol-degrading enzyme (e.g., ADH or AOX), the enzyme activity (particularly the specific activity of the enzyme) in the liposomes and / or polymeric vesicles can be in the range of 1-500 U / mg protein, for example, 10-450 U / mg protein, for example, 25-400 U / mg protein, for example, 50-375 U / mg protein, for example, 100-350 U / mg protein, for example, 200-325 U / mg protein, for example, 250-310 U / mg protein, for example, about 300 U / mg protein.

[0080] In a further embodiment of the invention, when the protein may be catalase or the like, the enzyme activity (especially the specific activity of the enzyme) in the liposomes and / or polymer vesicles may be in the range of 1-10000 U / mg protein, for example, 100-9000 U / mg protein, for example, 250-8000 U / mg protein, for example, 500-7000 U / mg protein, for example, 500-6500 U / mg protein, for example, 1000-6000 U / mg protein, for example, 2000-5500 U / mg protein, for example, 4000-5200 U / mg protein, for example, 2000-5500 U / mg protein, for example, about 5000 U / mg protein.

[0081] Enzyme activity, or specific activity, can be determined as the enzyme activity per milligram of total protein over time (e.g., expressed in μmol / min per mg of protein).

[0082] Improved enzyme activity (especially specific enzyme activity) and / or enzyme quantity in liposomes and / or polymeric vesicles can provide improved digestibility of ethanol in the stomach.

[0083] In one embodiment of the invention, the composition according to the invention may be able to degrade ethanol in the range of 50-5000 mM per hour, for example, 100-4000 mM per hour, 150-3000 mM per hour, 200-2500 mM per hour, 300-2000 mM per hour, 400-1800 mM per hour, 500-1500 mM per hour, 600-1300 mM per hour, 750-1200 mM per hour, 900-1100 mM per hour, or 950-1000 mM per hour.

[0084] Preferably, the hourly ethanol degradation can be determined per unit dose as described herein.

[0085] Preferably, the term "degradation" of ethanol according to the present invention may involve the conversion of ethanol into acetaldehyde, acetic acid, etc.

[0086] The liposomes and / or polymer vesicles according to the present invention are active in the human stomach, rather than in human blood or liver, and degrade ethanol.

[0087] The liposomes and / or polymer vesicles according to the invention can provide stability across different pH ranges. Preferably, the liposomes and / or polymer vesicles can provide stability to internal pH (e.g., stability to internal pH in the range of pH 6.0-8.5) and stability to external pH (e.g., stability to external pH in the range of pH 2.0-5.0).

[0088] In one embodiment of the invention, liposomes and / or polymeric vesicles can be stable in a pH range of 2.0-8.5, for example, in a pH range of 2.5-8.0, or for example, in a pH range of 3.0-7.5.

[0089] Preferably, the pH inside the liposomes and / or polymer vesicles may be higher than pH 6.0, such as pH 6.5 or higher, such as pH 7.0 or higher, such as pH 7.5 or higher, such as pH 8.0 or higher, such as pH 8.2 or higher, such as pH 8.5 or higher.

[0090] The compositions according to the invention may contain liposomes and / or polymeric vesicles that are stable at acidic pH.

[0091] The term "stable at acidic pH" can refer to the stability of liposomes and / or polymeric vesicles when subjected to an external environment with an acidic pH.

[0092] In one embodiment of the invention, the term "stable at acidic pH" may be used in conjunction with liposomes or polymeric vesicles and may refer to the liposomes or polymeric vesicles maintaining their structure at acidic pH, such that one or more enzymes within the liposomes or polymeric vesicles remain active. Acidic pH is a typical pH value of the human stomach, such as pH 3.0 or pH 2.0. The pH in the stomach may be higher due to food and beverage intake. Preferably, the term "stable at acidic pH" means that liposomes or polymeric vesicles encapsulating enzymes capable of degrading ethanol retain at least 20% of their enzyme activity after 15 minutes following the test specified in Example 4.

[0093] This provides stability at acidic pH levels, allowing enzymes to degrade ethanol in the human stomach without collapsing or degrading due to the gastric fluid environment (containing various acids and proteases).

[0094] Preferably, the liposomes and / or polymeric vesicles are stable at acidic pH, preferably at pH 5.5 or lower, such as at pH 5.0 or lower, such as at pH 4.5 or lower, such as at pH 4.0 or lower, such as at pH 3.5 or lower, such as at pH 3.0 or lower, such as below pH 2.5, such as below pH 2.0.

[0095] It can provide stability (e.g., acid stability) for a sufficient period of time to degrade at least part of the ethanol consumed.

[0096] Preferably, the liposomes and / or polymer vesicles are stable for a period of 20-300 minutes, such as 25-240 minutes, 30-180 minutes, 35-160 minutes, 40-140 minutes, 45-120 minutes, 50-100 minutes, 55-90 minutes, 58-80 minutes, or 60-70 minutes.

[0097] Preferably, the liposomes and / or polymeric vesicles are stable at acidic pH (especially at pH below 5.5 or lower, such as at pH 5.0 or lower, such as pH 4.5 or lower, such as pH 4.0 or lower, such as pH 3.5 or lower, such as pH 3.0 or lower, such as below pH 2.5, such as below pH 2.0) for a sufficient period of time to degrade at least a portion of the consumed ethanol (e.g., a period of 20-300 minutes, such as a period of 25-240 minutes, such as a period of 30-180 minutes, such as a period of 35-160 minutes, such as a period of 40-140 minutes, such as a period of 45-120 minutes, such as a period of 50-100 minutes, such as a period of 55-90 minutes, such as a period of 58-80 minutes, such as a period of 60-70 minutes).

[0098] In one embodiment of the invention, liposomes and / or polymer vesicles: - Has an internal pH higher than pH 6.0, such as pH 6.5 or higher, such as pH 7.0 or higher, such as pH 7.5 or higher, such as pH 8.0 or higher, such as pH 8.2 or higher, such as pH 8.5 or higher; - Stable when subjected to external environments with pH values ​​below pH 5.5 or lower, such as pH 5.0 or lower, such as pH 4.5 or lower, such as pH 3.5 or lower, such as pH 3.0 or lower, such as below pH 2.5; and - Maintain stability for a period of 20-300 minutes, such as a period of 25-240 minutes, a period of 30-180 minutes, a period of 35-160 minutes, a period of 40-140 minutes, a period of 45-120 minutes, a period of 50-100 minutes, a period of 55-90 minutes, a period of 58-80 minutes, or a period of 60-70 minutes.

[0099] The compositions according to the present invention can be ingestible compositions.

[0100] As used herein, the term "ingestible composition" is intended to mean a composition suitable for human consumption, i.e., a composition that is ingested by a person for or as if intended for digestion. Ingestible compositions can be solid compositions, liquid compositions, dry compositions, etc. Non-limiting examples of ingestible compositions may include food, beverage, tablet, pill, or liquid liposome and / or polymer vesicle compositions.

[0101] In another embodiment of the invention, the composition may be a liquid composition, and in particular, the liquid composition may be an aqueous composition.

[0102] The liquid composition according to the invention may comprise liposomes encapsulating an enzyme capable of degrading ethanol, wherein the liposomes may be suspended in the liquid composition.

[0103] In one embodiment of the invention, the liquid phase surrounding the liposomes and / or polymer vesicles of the liquid composition according to the invention may contain a buffer solution.

[0104] In a further embodiment of the invention, the liquid phase surrounding the liposomes and / or polymer vesicles of the liquid composition according to the invention may contain a preservative.

[0105] In one embodiment of the invention, the liquid phase (preferably aqueous phase) within the liposomes and / or polymer vesicles is substantially isotonic with the liquid phase (preferably aqueous phase) outside the liposomes and / or polymer vesicles.

[0106] In one embodiment of the invention, the composition may be a dried composition, a powder composition, or a pill / tablet containing the composition.

[0107] Preferably, the dried composition, powder composition, or pills / tablets containing the composition can be provided by applying various drying techniques such as freeze drying, spray drying, spray freeze drying, electrohydrodynamics, and supercritical methods.

[0108] When the compositions according to the invention are available as dry compositions and / or powder compositions, the dry compositions and / or powder compositions can be resuspended in the liquid component, particularly the aqueous component, before consumption.

[0109] Liposomes can be formed from various lipids, such as phosphatidylcholine. Useful phosphatidylcholine (PC) can be dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), distearyl phosphatidylcholine (DSPC), dioleoyl phosphatidylcholine (DOPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC), or naturally derived phosphatidylcholine (PC). Phosphatidylcholine can be obtained from a variety of different sources, including plant or animal materials. Plant materials are preferably selected from soybeans or sunflowers. Animal materials can be from cattle (e.g., beef or milk), fish, or chickens (especially eggs). Preferably, the animal material is an egg.

[0110] Preferably, the liposomes contain phosphatidylcholine obtained from soybeans, sunflowers, and / or eggs.

[0111] Useful phosphatidylglycerols (PGs) are dimyristoyl phosphatidylglycerol (DMPG), dipalmitoyl phosphatidylglycerol (DPPG), distearate phosphatidylglycerol (DSPG), and dicapryloyl phosphatidylglycerol (DOPG). Useful phosphatidylethanolamines (PEs) can be 1,2-dimyristoyl-sn-glycerol-3-phosphate ethanolamine (DMPE) and 1,2-dispalmitoyl-sn-glycerol-3-phosphate ethanolamine (DPPE). Useful phosphatidylserines (PSe) can be dimyristoyl phosphatidylserine (DMPS) and dipalmitoyl phosphatidylserine (DPPS). Useful sphingomyelins (SMs) can be palmitoyl sphingomyelin.

[0112] Further useful lipid components that can help modulate the properties of liposomes and / or polymeric vesicles may be sterols. Modified properties may include enhancing the stability of liposomes.

[0113] Sterols are amphiphilic lipids found in most eukaryotes, including animals, plants, and fungi. Sterols have a sterane structure and the molecular formula C6H2O. 17 H 28 O is derived from steranes by replacing the hydrogen atom at position 3 with a hydroxyl group.

[0114] Preferably, at least one sterol may be selected from cholesterol, phytosterols, lanosterol, and ergosterol. More preferably, at least one sterol may be cholesterol or phytosterols. Even more preferably, at least one sterol may be cholesterol.

[0115] In one embodiment, the liposomes or polymeric vesicles contain at least one sterol in an amount ranging from 10% to 60% (mol / mol), 10% to 50% (mol / mol), 15% to 40% (mol / mol), or 20% to 35% (mol / mol), for example, about 30% (mol / mol) of the liposomes or polymeric vesicles.

[0116] The liposomes and / or polymeric vesicles according to the invention may contain 40-100% (mol / mol) of phospholipids, for example, 50-90% (mol / mol) of phospholipids, for example, 60-80% (mol / mol) of phospholipids, for example, about 70% (mol / mol) of phospholipids.

[0117] In one embodiment of the invention, the liposomes and / or polymeric vesicles comprise 10-60% (mol / mol) of sterols (preferably cholesterol), such as 15-50% (mol / mol) of sterols (preferably cholesterol), such as 20-40% (mol / mol) of sterols (preferably cholesterol), such as 25-35% (mol / mol) of sterols (preferably cholesterol), such as about 30% (mol / mol) of sterols (preferably cholesterol), and 40-100% (mol / mol) of phospholipids, such as 50-90% (mol / mol) of phospholipids, such as 60-80% (mol / mol) of phospholipids, such as about 70% (mol / mol) of phospholipids.

[0118] There are many known enzymes for degrading ethanol, and they originate from prokaryotic and eukaryotic cells. Alcohol dehydrogenases (ADHs) catalyze the oxidation of alcohols to aldehydes or ketones, for example, through the following catalytic reactions: Ethanol + NAD + Acetaldehyde + NADH + H + The electron acceptor is nicotinamide adenine dinucleotide (NAD). + It should be understood that liposomes or polymeric vesicles encapsulating ADH used for ethanol degradation must also contain NAD during ethanol degradation. + Or another suitable electron acceptor.

[0119] In one embodiment of the invention, the composition comprises encapsulated ADH and NAD. + Liposomes or polymer vesicles.

[0120] In another embodiment, the composition comprises encapsulated ADH and NAD capable of regenerating from NADH. + The enzyme is a liposome or polymer vesicle.

[0121] In another embodiment, the composition comprises encapsulated ADH and NAD. + and the ability to regenerate NAD from NADH + The enzyme is a liposome or polymer vesicle.

[0122] Regenerating NAD from NADH + It can be catalyzed by a variety of enzymes, such as NADH oxidase, which can catalyze the following reactions: NADH + H + + O2 NAD + + H2O2 NADH + H + + ½ O2 NAD + + H2O In another embodiment, the composition according to the invention may comprise liposomes and / or polymeric vesicles encapsulating ADH and NADH oxidases.

[0123] In another embodiment, the composition comprises encapsulated ADH and NAD. + Liposomes and / or polymeric vesicles containing NADH oxidase.

[0124] Regenerate NAD + Another option is NADH peroxidase, which catalyzes the following reaction: NADH + H2O2 NAD + + 2 H2O NADH peroxidase can be found in Enterococcus faecalis ( Streptococcus faecalis ATCC 11700, and is commercially available, for example, from NZYTech (catalog number AE00201). In this invention, NADH peroxidase may be particularly useful when used in combination with hydrogen peroxide-producing oxidases (e.g., AOX or ALOX).

[0125] It should be understood that different methods than NAD can be used. + / NADH redox system dehydrogenases. One such system could be the ubiquinone / ubiquinol system.

[0126] Alcohol dehydrogenase (quinone) can be an enzyme with the systematic name alcohol:quinone oxidoreductase, which catalyzes the following reactions: Ethanol + ubiquinone Acetaldehyde + Panthenol Since acetaldehyde, produced from the degradation of ethanol by ADH in the digestive system, can cause various adverse effects, it is necessary to degrade acetaldehyde. One approach is to oxidize acetaldehyde to acetic acid, which is abundant in food and does not have the same adverse effects.

[0127] The degradation of acetaldehyde can be accomplished using aldehyde dehydrogenase (ALDH), which catalyzes the following reaction: Acetaldehyde + NAD + Acetic acid + NADH + H + In another embodiment, the composition comprises encapsulated ADH, ALDH, and NAD capable of regenerating from NADH. + The enzyme's liposomes and / or polymeric vesicles.

[0128] In another embodiment, the composition comprises encapsulated ADH, ALDH, and NAD. +and the ability to regenerate NAD from NADH + The enzyme's liposomes and / or polymeric vesicles.

[0129] In another embodiment, the ingestible composition comprises liposomes or polymeric vesicles encapsulating ADH, ALDH, and NADH oxidases.

[0130] In another embodiment, the composition comprises encapsulated ADH, ALDH, and NAD. + Liposomes and / or polymeric vesicles containing NADH oxidase.

[0131] Another option for degrading acetaldehyde is aldehyde oxidase (ALOX), which catalyzes the following reaction: Aldehyde + H2O + O2 Carboxylic acid + H₂O₂ + H + Hydrogen peroxide can be eliminated naturally in the stomach and intestines, but it can also be rapidly eliminated by catalase (CAT), a highly efficient enzyme. Catalase (CAT) catalyzes the following reactions: 2 H2O2 2 H2O + O2 In one embodiment, the composition comprises encapsulated ADH, ALOX, and NAD capable of regenerating from NADH. + The enzyme's liposomes and / or polymeric vesicles.

[0132] In another embodiment, the composition comprises encapsulated ADH, ALOX, CAT, and NAD capable of regenerating from NADH. + The enzyme's liposomes and / or polymeric vesicles.

[0133] In another embodiment, the composition comprises encapsulated ADH, ALOX, and NAD. + and the ability to regenerate NAD from NADH + The enzyme's liposomes and / or polymeric vesicles.

[0134] In another embodiment, the composition comprises encapsulated ADH, ALOX, CAT, and NAD. + and the ability to regenerate NAD from NADH + The enzyme's liposomes and / or polymeric vesicles.

[0135] In another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating ADH, ALOX, and NADH oxidases.

[0136] In another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating ADH, ALOX, CAT and NADH oxidases.

[0137] In another embodiment, the composition comprises encapsulated ADH, ALOX, and NAD. + Liposomes and / or polymeric vesicles containing NADH oxidase.

[0138] In another embodiment, the composition comprises encapsulated ADH, ALOX, CAT, and NAD. + Liposomes and / or polymeric vesicles containing NADH oxidase.

[0139] Preferably, the composition according to the invention may comprise liposomes and / or polymer vesicles encapsulating the following substances: Alcohol oxidase (AOX), aldehyde oxidase (ALOX), or a combination thereof; and Catalase (CAT), and Optional to exclude NAD + Or NADH or other cofactors.

[0140] In yet another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating formate oxidase, for example, derived from Aspergillus oryzae (… Aspergillus oryzae Formate oxidase is used to degrade acetaldehyde.

[0141] In yet another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating ADH and formate oxidase (e.g., from Aspergillus oryzae) to degrade acetaldehyde.

[0142] In another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating lactate oxidase, such as those from *Bacillus aureus*. Aerococcus viridans Lactate oxidase (LPO) degrades acetaldehyde.

[0143] In another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating ADH and lactate oxidase (e.g., from *Bacillus viride*) to degrade acetaldehyde.

[0144] Preferably, the composition comprising liposomes and / or polymeric vesicles according to the present invention can also degrade ethanol by encapsulating alcohol oxidase (AOX), the alcohol oxidase catalyzing the reaction: Ethanol + O2 Acetaldehyde + H2O2 In this implementation, NAD is not required. + Instead of the NADH redox system, O2 / H2O2 is used as the redox system. Therefore, AOX using the O2 / H2O2 redox system is preferred as an alternative to ADH.

[0145] In a preferred embodiment of the invention, the enzyme relies on a redox system that can readily diffuse across the cell membranes of liposomes and / or polymer vesicles. In this system, ethanol and oxygen (O2) readily diffuse across the cell membranes of liposomes and / or polymer vesicles, entering from the stomach into the liposomes and / or polymer vesicles, and reaction products such as acetaldehyde, acetic acid, and / or hydrogen peroxide readily diffuse out across the cell membranes of the liposomes and / or polymer vesicles.

[0146] In a further embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating alcohol oxidase (AOX).

[0147] In another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating AOX and ALOX.

[0148] In another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating AOX, ALOX, and an enzyme capable of eliminating hydrogen peroxide.

[0149] In another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating AOX, ALOX, and CAT.

[0150] In another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating AOX, ALOX, and NADH peroxidases.

[0151] In another embodiment, the composition comprises liposomes and / or polymeric vesicles encapsulating AOX and ALDH.

[0152] In another embodiment, the composition comprises encapsulated AOX, ALDH, and NAD. + Liposomes and / or polymeric vesicles.

[0153] In another embodiment, the composition comprises encapsulated AOX, ALDH, and NAD. + and the ability to regenerate NAD from NADH + The enzyme's liposomes and / or polymeric vesicles.

[0154] In another embodiment, the composition comprises encapsulated AOX, ALDH, and NAD. + Liposomes and / or polymeric vesicles containing NADH oxidase.

[0155] In another embodiment, the composition comprises encapsulated AOX (e.g., derived from *Phanerochaete chrysosporium*). P. chrysosporium )) of liposomes and / or polymer vesicles.

[0156] In another embodiment, the composition comprises liposomes and / or polymeric vesicles of encapsulating enzyme AOX (e.g., obtained from Phanerochaete chrysosporium F101S).

[0157] In yet another embodiment, the composition comprises encapsulated AOX (e.g., obtained from Pichia pastoris). Pichia pastoris or Hansenula polymorpha (Hanseluna spp )) of liposomes and / or polymer vesicles.

[0158] Preferably, the enzyme capable of degrading ethanol can be alcohol oxidase (AOX).

[0159] In a preferred embodiment of the invention, the composition may be an oral formulation comprising the composition according to the invention, wherein the composition comprises liposomes and / or polymer vesicles, and wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol.

[0160] The compositions according to the invention and / or oral formulations according to the invention may preferably be provided for the degradation of ethanol in the stomach.

[0161] The inventors of this invention have surprisingly discovered that the amount of cofactors added to (or encapsulated in) liposomes and / or polymer vesicles, particularly NAD, can be limited. + / NADH, thereby reducing the activity of such enzyme systems, since their function is in the stomach. Therefore, the inventors of this invention have discovered that using cofactors capable of diffusing through liposomes and / or polymer vesicles significantly improves the degradation of ethanol in the stomach.

[0162] A preferred embodiment of the present invention relates to a composition comprising liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol, wherein the liposomes and / or polymer vesicles do not encapsulate cofactors.

[0163] In particular, the present invention relates to a composition comprising liposomes and / or polymeric vesicles, wherein the liposomes and / or polymeric vesicles encapsulate an enzyme capable of degrading ethanol, wherein the liposomes and / or polymeric vesicles do not encapsulate NAD. + Or NADH or NADH oxidase.

[0164] A preferred embodiment of the present invention relates to a composition comprising liposomes and / or polymeric vesicles, wherein the liposomes and / or polymeric vesicles encapsulate AOX and / or ALOX, and are NAD-free. + Or NADH or NADH oxidase.

[0165] Preferably, the composition according to the invention comprises encapsulated AOX and / or ALOX and is free of NAD.+ Liposomes and / or polymeric vesicles containing NADH or another cofactor or NADH oxidase.

[0166] In another embodiment of the invention, the composition comprises encapsulated AOX and / or ALOX combined with CAT (catalase) and is NAD-free. + Liposomes and / or polymeric vesicles containing NADH or another cofactor or NADH oxidase.

[0167] For this type of product that does not contain cofactors or NAD + In a system with NADH (or without NADH oxidase), oxygen from the stomach can act as a cofactor, and this oxygen can diffuse across the membrane into liposomes and / or polymeric vesicles, assisting in enzymatic reactions and ethanol degradation.

[0168] Thus, the enzyme-catalyzed reaction is not affected by cofactors or NAD. + The limitations of NADH availability allow for efficient alcohol degradation in the stomach, rather than relying on degradation in the gut.

[0169] In one embodiment of the invention, the liposomes and / or polymer vesicles according to the invention can be configured to allow small molecules such as ethanol, acetaldehyde, acetic acid, oxygen, etc., to diffuse across the cell membrane of the liposomes and / or polymer vesicles.

[0170] In one embodiment of the invention, small molecules such as ethanol, acetaldehyde, acetic acid, oxygen, etc. are permitted or able to diffuse through the cell membrane of the liposomes and / or polymer vesicles according to the invention.

[0171] The liposomes and / or polymer vesicles according to the present invention can be partially or completely degraded in the human stomach.

[0172] In one embodiment of the invention, the partially degraded liposomes and / or polymer vesicles according to the invention may involve the degradation of at least 50% of the liposomes and / or polymer vesicles in the human stomach, for example, at least 60% of the liposomes and / or polymer vesicles, for example, at least 70% of the liposomes and / or polymer vesicles, for example, at least 80% of the liposomes and / or polymer vesicles, for example, at least 90% of the liposomes and / or polymer vesicles, for example, at least 95% of the liposomes and / or polymer vesicles, for example, at least 98% of the liposomes and / or polymer vesicles.

[0173] Unbound by theory, the inventors of this invention believe that the configuration of liposomes and / or polymer vesicles according to the invention ensures that liposomes and / or polymer vesicles that are not degraded in the stomach can be secreted primarily via the gastrointestinal tract.

[0174] In one embodiment of the invention, liposomes and / or polymer vesicles are preferably not present in the blood of a person consuming the composition or oral formulation of the invention.

[0175] Preferably, less than 25% of the contents of the liposomes and / or polymer vesicles consumed by a person may be present in the blood and / or liver of a person consuming the composition according to the invention, for example less than 20%, for example less than 15%, for example less than 10%, for example less than 5%, for example less than 2%, for example less than 1%, for example less than 0.5%, for example less than 0.1%, for example less than 0.01%, for example less than 0.001%.

[0176] A preferred embodiment of the invention relates to a unit dose comprising the composition according to the invention, wherein the unit dose comprises an enzyme of 50 U / unit dose or higher, the enzyme being encapsulated in liposomes and / or polymer vesicles.

[0177] The unit dose according to the invention can be provided as a liquid composition (e.g., an aqueous composition) or a dry composition (e.g., as a tablet or pill).

[0178] In one embodiment of the invention, the composition may be provided as a liquid composition, with each unit dose comprising a volume in the range of 1-200 ml, for example, 5-150 ml, for example, 10-100 ml, for example, 20-90 ml, for example, 30-80 ml, for example, 35-70 ml, for example, 40-60 ml, for example, 45-55 ml, for example, about 50 ml.

[0179] In a further embodiment of the invention, the composition may be provided as a dried composition, for example as a pill or tablet, in unit doses comprising 50-20000 U of liposomes and / or polymeric vesicles per pill / tablet, for example, 100-19000 U per pill / tablet, for example, 500-18000 U per pill / tablet, for example, 1000-17000 U per pill / tablet, for example, 2000-16000 U per pill / tablet, for example, 3000-15000 U per pill / tablet, for example, 4000-14000 U per pill / tablet, for example, 5000-13000 U per pill / tablet, for example, 6000-12000 U per pill / tablet, for example, 7000-11000 U per pill / tablet, for example, 8000-10000 U per pill / tablet. Within the range of U, for example, approximately 9000 U per pill / tablet.

[0180] Preferably, the unit dose according to the invention may contain an enzyme capable of degrading ethanol, said enzyme being encapsulated in liposomes and / or polymer vesicles, and wherein the enzyme may be provided in an amount of 50 U / unit dose or higher, such as 75 U / unit dose or higher, such as 100 U / unit dose or higher, such as 125 U / unit dose or higher, such as 150 U / unit dose or higher, such as 175 U / unit dose or higher, such as 200 U / unit dose or higher, such as 250 U / unit dose or higher, such as 300 U / unit dose or higher, such as 350 U / unit dose or higher, such as 400 U / unit dose or higher, such as 500 U / unit dose or higher, such as 600 U / unit dose or higher, such as 700 U / unit dose or higher, such as 800 U / unit dose or higher, such as 900 U / unit dose or higher, such as 1500 U / unit dose or higher, such as 2000 U / unit dose or higher, such as 3000 U / unit dose or higher. U / unit dose or higher, such as 4000 U / unit dose or higher, such as 5000 U / unit dose or higher, such as 6000 U / unit dose or higher, such as 7000 U / unit dose or higher, such as 8000 U / unit dose or higher, such as 9000 U / unit dose or higher, such as 10000 U / unit dose or higher, such as 11000 U / unit dose or higher, such as in the range of 50-17500 U / unit dose, such as in the range of 100-15000 U / unit dose, such as in the range of 150-12000 U / unit dose, such as in the range of 250-10000 U / unit dose, such as in the range of 500-8500 U / unit dose, such as in the range of 1000-7500 U / unit dose, such as in the range of 1500-6000 U / unit dose, such as in the range of 2000-5500 U / unit dose, such as in the range of 2500-5000 U / unit dose. Within the range of U / unit dose, for example, 3000-4500U / unit dose, for example, 3500-4000U / unit dose.

[0181] Various factors can affect the stability of liposomes and / or polymeric vesicles, such as temperature, pH, surface charge, and / or the lipid composition used to prepare liposomes and / or polymeric vesicles.

[0182] The stomach is a J-shaped organ, resulting in one side having a smaller bend and the other a larger bend. It connects to the esophagus, where food and liquids enter, and to the duodenum, where processed contents exit. The stomach's inner surface is composed of irregular folds (folds), increasing surface area and allowing the stomach to expand during meals. Approximately 1.5 L of fluid is secreted into the stomach daily from gastric glands. Hydrochloric acid (HCl) is secreted to lower the pH to approximately 2. This ensures that most microorganisms entering the stomach are killed. Additionally, pepsinogen (a precursor to pepsin) is secreted into the stomach. Pepsin breaks down proteins in the stomach. The extreme acidity and pepsin within the stomach represent a harsh environment for enzymes, including most of the ingestible components that enter the stomach.

[0183] To improve the stability of liposomes and / or polymer vesicles, various methods can be implemented to stabilize them. These methods may include surface modification, membrane stabilization, alteration of lipid composition, and addition of surfactants and nanoparticles.

[0184] Some of these methods for stabilizing liposomes and / or polymer vesicles may include: - PEGylation (polyethylene glycol), etc., may involve attaching polyethylene glycol chains to the surface of liposomes and / or polymer vesicles. PEGylation, etc., can increase liposome stability by providing steric hindrance, reducing aggregation, and / or opsonization. Coating with polysaccharides such as hyaluronic acid, dextran, chitosan, and alginate can be used to coat liposomes and / or polymer vesicles. These polysaccharide coatings can improve the stability, biocompatibility, and targeting ability of liposomes. Furthermore, polysaccharides can provide ligand conjugation sites, which can impart additional functionality to liposomes and / or polymer vesicles if needed. Protein and / or peptide conjugation or adsorption: Proteins or peptides on the surface of liposomes and / or polymer vesicles can improve stability. Lipid bilayer modification can be provided by incorporating components such as phospholipids (e.g., PEG-lipids modified with polyethylene glycol) or charged lipids (e.g., positively charged lipids such as stearamide or fusion lipids such as cholesterol hemisuccinate) into liposomes and / or polymeric vesicle bilayers to provide stability and stealth properties.

[0185] Other types of surface-active molecules (such as amphiphilic molecules, like surfactants or block copolymers) or zwitterionic lipids (which may contain positively and negatively charged groups) can be adsorbed onto liposomes and / or polymer vesicles and used as a coating, and can further stabilize liposomes and / or polymer vesicles.

[0186] In one embodiment of the invention, liposomes and / or polymer vesicles may be provided with one or more surface modifications. Preferably, the one or more surface modifications may be PEGylation, encapsulation (e.g., using polysaccharides), conjugation or adsorption of proteins and / or peptides, lipid bilayer modification, or a combination thereof.

[0187] In addition, nanocarriers can be used to stabilize therapeutic compounds, including enzymes. Nanocarriers can have different sizes, functional properties, and stabilization mechanisms. However, nanocarriers are only one way to stabilize enzymes. Enzymes can also be stabilized through protein engineering, chemical modification, cross-linking, or the addition of additives.

[0188] By selecting appropriate methods to improve or control the stabilization of liposomes and / or polymer vesicles, the inventors of this invention can adjust the stabilization time of liposomes and / or polymer vesicles in the stomach and improve their activity in degrading ethanol present in the human stomach.

[0189] The stability of liposomes and / or polymer vesicles intended for ingestion and entry into the stomach has been surprisingly further improved. For example, liposomes and / or polymer vesicles can be coated with a polymer layer to increase their stability. Another approach is the PEGylation of liposomes and / or polymer vesicles, which has been shown to increase circulation time in the blood and stomach, and may potentially inhibit pancreatic lipases.

[0190] The compositions comprising liposomes and / or polymer vesicles according to the present invention can be prepared in different ways; however, the inventors of the present invention have discovered a preferred method for preparing the compositions according to the present invention.

[0191] A preferred embodiment of the present invention relates to a method for preparing a composition comprising liposomes and / or polymer vesicles according to the present invention, the method comprising the following steps: a) Dissolve phospholipids in an organic solvent. b) Hydrate the phospholipids with an aqueous solution of at least one enzyme that degrades ethanol. c) Freeze the hydrated lipids in liquid nitrogen. d) Thaw in an aqueous solution at 20°C and freeze in liquid nitrogen, repeating at least 3 cycles. e) Optional extrusion to obtain more uniform dimensions. This yields a composition containing liposomes and / or polymer vesicles.

[0192] Liposomes can be prepared using the following procedure: 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC) is dissolved in chloroform, and the chloroform is evaporated under a weak nitrogen stream, followed by vacuum evaporation. After complete evaporation of the chloroform, the lipids are hydrated to form liposomes. This is accomplished by slowly adding a buffer containing the relevant enzymes and optional cofactors, freezing in liquid nitrogen, and then thawing in water at room temperature (20°C). The freeze-thaw cycle is repeated seven times to increase the formation of monolayer liposomes. To obtain more uniform liposomes, extrusion can be performed, for example, at 800 nm. This size ensures that each liposome contains a number of enzymes and optional cofactors. Liposome size can be determined using dynamic light scattering (DLS).

[0193] A preferred embodiment of the present invention relates to a kit comprising a composition according to the present invention and an instruction manual according to the present invention.

[0194] A further preferred embodiment of the invention relates to the use of the composition according to the invention for the degradation of ingested ethanol in the stomach.

[0195] The composition according to the invention can be administered to individuals suffering from alcohol intolerance.

[0196] A preferred embodiment of the invention relates to the use of liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol for the preparation of a composition according to the invention for the degradation of ingested ethanol in the stomach.

[0197] In one embodiment of the invention, the composition according to the invention is used to degrade ingested ethanol in the stomach, wherein an individual suffering from alcohol intolerance self-administers the composition.

[0198] A further embodiment of the invention relates to the use of liposomes and / or polymer vesicles, wherein the liposomes and / or polymer vesicles encapsulate an enzyme capable of degrading ethanol for the preparation of a composition according to the invention for the treatment or prevention of alcohol poisoning.

[0199] The compositions according to the invention may be ingested by an individual before and / or after consuming ethanol (e.g., alcoholic beverages).

[0200] Preferably, the composition according to the invention can be taken (preferably by swallowing) within a period of 30 minutes before and / or no later than 30 minutes after consuming ethanol (e.g., one or more alcoholic beverages). Even more preferably, the composition according to the invention can be taken (preferably by swallowing) within a period of 15 minutes before and / or no later than 15 minutes after consuming ethanol (e.g., one or more alcoholic beverages). Even more preferably, the composition according to the invention can be taken (preferably by swallowing) within a period of 10 minutes before and / or no later than 10 minutes after consuming ethanol (e.g., one or more alcoholic beverages). Even more preferably, the composition according to the invention can be taken (preferably by swallowing) within a period of 5 minutes before and / or no later than 5 minutes after consuming ethanol (e.g., one or more alcoholic beverages).

[0201] The compositions according to the present invention are used to treat, prevent or alleviate alcohol flushing.

[0202] It should be noted that the embodiments and features described in the context of one aspect of the invention are also applicable to other aspects of the invention.

[0203] All patent and non-patent references cited in this application are incorporated herein by reference in their entirety.

[0204] The present invention will now be described in further detail in the following non-limiting embodiments. Example

[0205] Example 1 - Ethanol degradation of liposome composition The degradation of ethanol using ADH is accompanied by NAD + Transformation means NAD + The amount of ADH and NAD determines how much ethanol can be broken down. + Encapsulated in liposomes, the liposomes exhibited activity. They were prepared using the following procedure: 40 mg of 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC) was dissolved in 1 mL of chloroform and aliquoted into two 4 mL glass vials. Glass pipettes were used. The vials could be stored overnight at -20°C if necessary. Both vials were placed in a fume hood under a weak nitrogen flow for 15 minutes to evaporate the chloroform. After evaporation under nitrogen, the chloroform was further evaporated under vacuum at 0.8 mbar for two hours. This was done instead of using a rotary evaporator. After complete evaporation of the chloroform, the lipids were hydrated to form liposomes. This was accomplished by slowly adding 2 mL of buffer. A negative control sample should also be prepared for subsequent measurements. This sample should be deficient in the enzyme or NAD in the hydration buffer. +Samples were frozen in liquid nitrogen and then thawed in water at room temperature (20°C). Increased freezing and thawing may denature the enzymes. The freeze-thaw cycle was repeated seven times to increase the formation of monolayer liposomes. To obtain more homogeneous liposome samples, extrusion was performed at 800 nm. This size ensures that each liposome contains a number of ADH enzymes and NAD+. + Molecules. Extrusion was performed using a handheld Mini-Extruder from AvantiPolar Lipids, Inc. The extruder was first washed with ethanol and milli-Q water. The liposome sample was then extruded once through an 800 nm pore filter membrane. Liposome size was then determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS size analyzer from Malvern Panalytical. As background, 40 mM Tris-HCl buffer at pH 8.5 with a 0.22 µm filter was used. 10 µL of sample was then diluted in 990 µL of filter buffer. Lipid concentration was not determined but could be measured using inductively coupled plasma mass spectrometry (ICP-MS). 50 mM Tris-HCl at pH 8.5 was used as the buffer. ADH and NAD + The concentrations varied. In the first round of preparation, 2 mg / mL ADH and 30 mMnAD were used. + The concentration. Empty liposomes consist of substances that do not contain ADH and NAD. + Preparation of hydration buffer solution.

[0206] In the second round of liposome preparation, two glass vials, each containing 20 mg of POPC, were hydrated with a hydration buffer containing 2 mg / mL ADH and 30 mM NAD. + The other two glass vials contained 0.5 mg / mL ADH and 100 mM NAD. + Hydrate with hydration buffer, while two additional glass vials contain 0.5 mg / mL ADH and 0 mM NAD. + Hydration. To ensure that each liposome contains the appropriate amount of enzymes and NAD. + Molecular calculations were performed, and we theoretically calculated how many units are in each liposome structure. This was done using 2 mg / mL ADH and 30 mM NAD. + With a concentration of [specific concentration] and a liposome size of 800 nm, we expect approximately 2152 ADH enzyme molecules and +4 million NAD molecules. + Molecules. This is calculated using the following formula: One mole = one unit in one liposome Where r lipo This is the expected radius of the liposome, and [molecule] is the concentration of a given molecule in the hydration buffer. This is Avogadro's constant. Desalting was performed using a GE Healthcare PD-10 column. Gravity protocol was followed. 50 mM Tris-HCl buffer at pH 8.5 was used as the equilibration buffer.

[0207] The eluent was collected as 1 mL of elution buffer, and the absorbance was measured at 280 nm using a NanoDrop 2000c spectrophotometer from Thermo Scientific. We expect free enzyme and free NAD to be present. + and containing NAD + Both the protein and its liposomes absorb light at this wavelength. NADH enzyme activity was measured in flat-bottomed 96-well plates with 200–300 µL of sample added. Samples were preferably added in duplicate or triplicate.

[0208] The absorbance was then measured at 340 nm using a Tecan Spark 20M multi-functional microplate reader and incubated at 25°C. Measurements were taken every minute for at least 30 minutes. Increased absorbance indicates increased NADH concentration, which in turn indicates enzyme activity. This is due to the increased activity of the cofactor NAD during ethanol degradation catalyzed by ADH. + Convert to NADH.

[0209] Figure 1 The encapsulation of ADH and NAD is shown. + The results of ethanol degradation by liposomes are shown. The curve below clearly shows that ADH is stable when encapsulated in liposomes and incubated at pH 4 for 15 minutes.

[0210] All samples were incubated at pH 4 for 15 minutes. Absorbance was measured at 340 nm, and was proportional to the NADH concentration. NADH is produced during the degradation of ethanol by ADH, while NAD... + Converted to NADH. Light blue indicates free ADH incubated at pH 4. The upper and middle curves are from liposomes encapsulated with ADH incubated at pH 4, with and without detergent.

[0211] Example 2 - Liposomes containing AOX that degrades ethanol.

[0212] Figure 2 The time-dependent effect of liposome encapsulated with AOX catalyzing the oxidation of 50 mM ethanol to H2O2 in phosphate buffer pH 3 is shown (upper line, marked). The mean H2O2 concentration produced by empty liposomes over time is shown (lower line, marked). Empty liposomes refer to liposomes that do not contain any enzyme. Therefore, this can be considered a negative control.

[0213] 20 mg of POPC was dissolved in 0.5 mL of dichloromethane. The phospholipid solution was allowed to evaporate completely, and then placed under vacuum for one hour to ensure complete evaporation of the dichloromethane. A thin white phospholipid film formed during evaporation. The film was slowly rehydrated with a small amount of hydration buffer (100 μL 0.1 M phosphate buffer, pH 7.5), containing 100 U / mL pAOX enzyme. Afterward, the liposome solution was mixed several times every 15 minutes using a flicking bottle after adding the remaining buffer (1.9 mL). The liposomes were then subjected to seven freeze-thaw cycles in liquid nitrogen and a 25–30 °C water bath. After the final freezing step, the sample was stored at -20 °C until the extrusion step. The extruded liposomes were purified by first centrifuging at 7000 crf for six minutes. After discarding the supernatant, the precipitate was resuspended in 1 mL of wash buffer (50 mM phosphate buffer, pH 7.5) and centrifuged again at 7000 crf for six minutes. The washing step was repeated three times. Finally, the precipitate was resuspended in 5 μL of 0.1 M phosphate buffer, pH 3. Ethanol degradation activity was then tested.

[0214] Example 3 - In vitro ADH and ALDH activity (free) of lipids Figure 3 The absorbance measured at 340 nm over time is shown. The absorbance corresponds to NADH production. Three samples were measured per minute for 5 minutes. Different enzyme samples were dissolved in Tris-HCl buffer at pH 8.5, containing NAD+. + And ethanol. Each sample shows a linear trend line. This clearly demonstrates that ALDH can break down acetaldehyde into acetic acid.

[0215] To determine the synergistic effect between ADH and ALHD, the initial rates were measured as follows: ADH, ALDH, and ADH+ALDH samples were prepared. Each well contained 0.1 U ADH and / or 0.5 U ALDH. All wells contained a final concentration of 0.1% (17.2 mM) ethanol and 12 mM NAD. + Prepare 50 mM Tris pH 8.5 buffer. Measure absorbance at 340 nm over 3 minutes, with 1-minute intervals. Prepare ADH, ALDH, and ADH+ALDH samples. Each well contains 0.02 U ADH and / or 0.1 U ALDH. All wells contain a final concentration of 0.01% (1.72 mM) ethanol and 6 mM NAD. + And 50 mM Tris pH 8.5 buffer.

[0216] The experiment was initiated simultaneously by adding ethanol using a multichannel pipette. Absorbance was measured at 340 nm at 2-10 minute intervals for a total duration of 800 minutes. Both experiments were performed at room temperature (RT) with biological double replicates and technical triple replicates.

[0217] Example 4 - Stability of enzymes in liposomes at acidic pH refer to Figure 4 The results are shown in the figure. The x-axis shows how many minutes the enzyme was treated in 50 mM phosphate buffer at pH 2. The y-axis shows the retention activity (%) at pH 2 relative to 0 minutes. After 30 minutes at pH 2, V2 retained approximately 100% activity, while the native enzyme retained 0.2%. The membrane of the V2 liposomes consisted of 30% cholesterol and 70% POPC, while V1 consisted of POPC only. The enzyme was ADH-containing in all cases. The native enzyme (black, left column) was unencapsulated and retained almost 0% activity after only half a minute at pH 2. The ADH-containing V1 liposomes (middle column) and V2 liposomes (right column) still showed activity after 60 minutes at pH 2. Stability was tested according to the standard activity assay method for the encapsulated enzyme. The sample was first removed from the pH 2 incubation by centrifugation and removal of the pH 2 buffer by pipetting. The liposome sample was then washed twice with 50 mM pH 7.5 phosphate buffer, and finally resuspended in 50 mM pH 7.5 phosphate buffer. In this case, the liposomes were then dissolved by adding sodium cholate, and the remaining activity of the releasing enzyme could then be tested. The ADH activity assay was performed in a solution containing NAD+. + The absorbance was measured at 340 nm in the solution of ethanol.

[0218] Example 5 - Peroxidase Activity Figure 5 The results of experiments performed using ALDH, AOX, and NADH peroxidases are shown. Both samples contained ALDH, AOX, 1% ethanol, 40 mM phosphate buffer (pH 7.5), and a limited amount of NAD. + One sample contained NADH peroxidase (right column), and the other did not (left column). After 4 hours, NADH (absorbance 340 nm), H2O2 (mM H2O2 produced), and ethanol (in %) were measured. NADH was measured directly by absorbance, while H2O2 and ethanol were measured using different coupled enzyme assays.

[0219] As expected, the results showed that NADH was only produced in systems lacking NADH peroxidase, and with less hydrogen peroxide produced. Furthermore, the addition of NADH peroxidase resulted in greater ethanol degradation. This must be due to the regeneration of NAD+ by the addition of NADH peroxidase. +This allows ALDH to degrade acetaldehyde (produced by AOX) into acetic acid. This alters the reaction equilibrium and rate, driving the degradation of ethanol.

[0220] Example 6 - NADH peroxidase can be used to regenerate NAD in liposomes. + .

[0221] Figure 6 The liposome-containing enzyme system was tested at pH 3. The enzyme system consisted of AOX, ALDH, and NADH peroxidases (NPs). The supernatant, consisting of hydration buffer, was tested at pH 7.5. In the ALDH and NADH assays, absorbance was measured at 340 nm and the values ​​are displayed on the y-axis. For the HRP assay, which measures peroxides, the peroxide concentration (mM) is displayed on the y-axis. The x-axis shows time (hours). For the NADH and acetaldehyde assays, single-repeat measurements were performed. For the HRP assay, double-repeat measurements were performed.

[0222] In this experiment, Escherichia coli (E. coli) was tested. E. coli The NADH peroxidase from *Enterococcus faecalis* expressed in [the image / sample]. This enzyme is relevant because it converts NADH and peroxides to NAD. + By using this enzyme in conjunction with ALDH, we ensure that NAD+ is utilized. + Continued supply. See also Figure 6 Explanation of this. The results for four samples are shown in the figure. Four different samples were prepared here: absorbance at 340 nm was measured at 0, 1.5, and 4 hours to measure NADH production, HRP was determined to measure peroxides, and acetaldehyde was determined. For the acetaldehyde determination, ALDH and NAD were added to the sample. + If any acetaldehyde is present, NADH should be produced, which will absorb light at 340 nm. The concentrations of acetaldehyde, NADH, and peroxide in the different samples are as expected. For both the supernatant and liposomes, acetaldehyde should be produced only in samples 2 and 3. NADH should be produced only in the supernatant of sample 3, not in the liposomes, as it will be trapped within the liposomes.

[0223] Peroxides should have been primarily produced in samples 2 and 3, which is indeed the case. This experiment should be repeated using an acetic acid kit from Abcam. This will demonstrate that acetic acid was primarily produced in sample 4 and show that NADH peroxidase does indeed regenerate NAD. + This allows for further ALDH catalysis to convert acetaldehyde into acetic acid.

[0224] Example 7 - Ethanol degradation (acetic acid formation) in a non-encapsulated enzyme system.

[0225] exist Figure 7In this study, the degradation of ethanol by an enzyme system consisting of AOX, ALDH, and NADH peroxidases (NP) under unencapsulated conditions at pH 7.5 was tested. Figure 7 The left side shows the absorbance measurement at 340 nm. This should measure the formation of NADH. NADH measurements were performed on a single sample. Figure 7 The middle section shows the results of peroxide measurement using the HRP assay. Figure 7 The right side shows the acetic acid kit measurements performed after the samples were incubated in ethanol for 4 hours. Peroxide and acetic acid concentrations were measured using a double-repeat technique. In the experiment, the ability of different samples to produce acetic acid was tested. The results are shown in the figure below. As expected, NADH was produced only in sample 3. This is due to the simultaneous presence of ALDH and NAD. + The samples 2 and 3 contained AOX but lacked NADH peroxidase. NADH levels were quite high at time 0 in sample 4. This is because the enzyme had already produced some NADH during the time prior to the actual measurement. HRP was detected in samples 2 and 3 because they contained AOX but lacked NADH peroxidase. No NADH or peroxides were measured in sample 4, believed to be due to the addition of NADH peroxidase. A univariate ANOVA was performed, with p-values ​​<0.0001 for testing whether samples were equal. Multiple comparisons between different means were performed. The p-value for the difference in acetic acid between samples 3 and 4 was 0.013. Therefore, the amount of acetic acid in sample 4 was significantly higher than in sample 3. This is most likely due to NADH peroxidase regenerating NAD. + The difference between Sample 4 and Samples 1 and 2 was even more significant. 324 ± 99.3 µM acetic acid was produced in Sample 3, while 2260 ± 572 µM acetic acid was produced in Sample 4.

[0226] Example 8 - Testing in a gastric model To better mimic the human stomach environment, we prepared simulated gastric juice. This increased complexity was important for understanding whether any gastric contents would affect the activity of the encapsulated enzymes. We decided to use FaSSGF from biorelevant, a preferred choice for several pharmaceutical companies and others for simulating fasting gastric juice.

[0227] exist Figure 8 In the figure, the y-axis shows µM peroxide, and the x-axis shows time (minutes). Measurements were performed in biological and technical double replicates. Samples 1 and 4 produced 1220 ± 49.74 µM H2O2 and 1453 ± 46.50 µM H2O2, respectively.

[0228] FaSSGF does not contain pepsin. To better simulate gastric juice, pepsin was added. As with other gastric models used in studies, we added 2600 U / mL pepsin in the following experiments. Four different samples were prepared and added to a simulated gastric model containing ethanol. The gastric model was prepared by mixing 100 µL of different samples with 200 µL of gastric juice and 700 µL of 1% ethanol in citrate buffer at pH 3.

[0229] In the gastric model, AOX liposomes in simulated gastric juice showed almost the same activity as the control in pH 3 citrate 80 mM buffer. Sample 1 produced 1220 ± 49.74 µM H2O2, and Sample 4 produced 1453 ± 46.50 µM H2O2. No activity was measured in either of the gastric models in Samples 2 and 3. This was expected, as these were negative controls. This tells us that the liposome system performs well in protecting enzymes from salts, acids, and proteases.

[0230] Example 9 - Synergistic effect of AOX and catalase in ethanol degradation.

[0231] Figure 9 The reaction rates of ethanol degradation are shown for liposomes loaded with 100 U / mL AOX, 400 U / mL catalase (CAT), and a combination of AOX and CAT (MIX). Error bars represent standard deviation. NADH produced per hour is shown in mM. The y-axis represents acetaldehyde concentration (mol).

[0232] During the conversion of AOX to ethanol, hydrogen peroxide is formed. The accumulation of hydrogen peroxide inactivates AOX, thus requiring its removal. Adding catalase to liposomes removes the generated hydrogen peroxide, preventing AOX inactivation. This leads to higher ethanol degradation because AOX is able to continue catalyzing ethanol oxidation. The measurement methods used involve the use of ALDH and NAD... + The amount of acetaldehyde produced in the solution was quantified by measuring the NADH produced.

[0233] The acetaldehyde produced is shown, which is equivalent to the degradation of ethanol. When catalase is present with AOX, it more than doubles the reaction rate, thereby more than doubling the production of NADH.

[0234] Example 10 - Effects of alcohol oxidase (AOX) and the use of O2 as a cofactor The liposomes used in Example 10 were prepared in the same manner as in Example 1, except that alcohol dehydrogenase (ADH) was replaced with alcohol oxidase (AOX) and NAD was not added. + Or NADH. Liposomes were placed in an aqueous solution containing ethanol and 0.2 mM oxygen (O2).

[0235] The result is Figure 10The figure shows the amount of ethanol degraded at 0 and 30 minutes in AOX-containing liposomes (10% and 20%) and the negative control (free AOX not encapsulated in liposomes). The linear regression equations for each time interval from 0 to 30 minutes are interpolated into the figure.

[0236] Ethanol degradation activity was measured using the HRP ABTS assay. Liposomes were prepared by ethanol injection with 40 U / mL AOX. The total volume was 500 µL, where 10% and 20% refer to the volume of the liposome precipitation solution. Free AOX was added at a final concentration of 5 U / mL and tested in 40 mM citric acid. All samples were treated with a final concentration of 2% ethanol.

[0237] Comparing the results of Example 10 with those of Example 1, it becomes apparent how surprisingly more active the liposome-based oxidase (AOX in this case) liposome system is compared to encapsulating an ADH (alcohol dehydrogenase) liposome. Here, we degraded more than 25 mM ethanol (expressed as H2O2 content) within 30 minutes, resulting in an activity of degrading more than 50 mM ethanol per hour. It is expected that the results will be further enhanced by adding catalase to remove H2O2 products and regenerate some oxygen. This principle is described in Example 9.

[0238] References A. Akbarzadeh, R. Rezaei-sadabady, S. Davaran, SW Joo, and N. Zarghami, “Liposome: classification, preparation, and applications,” pp. 1–9, 2013. Yoshimoto et al.: “Liposomal Encapsulation of Yeast AlcoholDehydrogenase with Cofactor for Stabilization of the Enzyme Structure and Activity”,BIOTECHNOL. PROG., 2008, Vol. 24, p 576-582. US 2021 / 0213107.

Claims

1. A composition comprising liposomes and / or polymersomes, wherein the liposomes and / or the polymersomes encapsulate an enzyme capable of degrading ethanol, wherein the enzyme capable of degrading ethanol (in ethanol decomposition) is assisted by a co-factor capable of diffusing through the cell membrane of the liposomes and / or the polymersomes.

2. The composition according to claim 1, wherein the enzyme capable of degrading ethanol according to the present application is independent of NAD + and / or NADH.

3. The composition according to claim 1 or 2, wherein the co-factor is oxygen (O2).

4. The composition according to any one of the preceding claims, comprising liposomes and / or polymersomes, the liposomes and / or the polymersomes encapsulating an enzyme capable of degrading ethanol, wherein the liposomes and / or polymersomes meet at least one of the following criteria: i. wherein the amount of the enzyme is higher than 100 U / ml of the composition; and / or ii. wherein the liposomes and / or the polymersomes comprise a particle size of at least 400 nm; and / or iii. wherein the composition is capable of degrading ethanol in the range of 50-5000 mM per hour.

5. The composition according to any one of claims 1-4, wherein the liposomes and / or polymersomes: - have an internal pH higher than pH 6.0, such as pH 6.5 or higher, such as pH 7.0 or higher, such as pH 7.5 or higher, such as pH 8.0 or higher, such as pH 8.2 or higher, such as pH 8.5 or higher; - are stable when subjected to an external environment with a pH lower than pH 5.5 or lower, such as pH 5.0 or lower, such as pH 4.5 or lower, such as pH 4.0 or lower, such as pH 3.5 or lower, such as pH 3.0 or lower, such as lower than pH 2.5, such as lower than pH 2.0; and - maintain stability for a period of time of 20-300 minutes, such as for a period of time of 25-240 minutes, such as for a period of time of 30-180 minutes, such as for a period of time of 35-160 minutes, such as for a period of time of 40-140 minutes, such as for a period of time of 45-120 minutes, such as for a period of time of 50-100 minutes, such as for a period of time of 55-90 minutes, such as for a period of time of 58-80 minutes, such as for a period of time of 60-70 minutes.

6. The composition according to any one of claims 1-5, wherein the composition is a liquid composition, in particular the liquid composition is an aqueous composition.

7. The composition according to any one of claims 1-5, wherein the composition is a dry composition, a powder composition or a pill / tablet comprising composition.

8. The composition according to any one of claims 1-7, wherein the liposomes and / or polymersomes comprise at least one solid sterol.

9. The composition according to any one of the preceding claims, wherein the enzyme capable of degrading ethanol is an alcohol oxidase (AOX), an aldehyde oxidase (ALOX) or a combination thereof.

10. The composition according to any one of the preceding claims, wherein the liposomes and / or the polymersomes comprise an enzyme activity in the range of 1-500 U / mg protein.

11. The composition according to any one of the preceding claims, wherein the liposome comprises phosphatidylcholine obtained from soybean, sunflower and / or egg.

12. The composition according to any one of the preceding claims, wherein the liposomes and / or the polymer vesicles are provided with one or more surface modifications.

13. The composition according to any one of the preceding claims, wherein the one or more surface modifications may be PEGylation, coating (e.g., using polysaccharides), conjugation or adsorption of proteins and / or peptides, lipid bilayer modification, or a combination thereof.

14. The composition according to any one of the preceding claims, wherein the liposomes and / or polymer vesicles are configured to perform ethanol degradation primarily in the human stomach.

15. A unit dose comprising a composition according to any one of claims 1-14, wherein the unit dose comprises an enzyme in an amount of 50 U / unit dose or higher, the enzyme being encapsulated in liposomes and / or polymer vesicles.

16. Use of the composition according to any one of claims 1-14 for the degradation of ingested ethanol in the stomach.

Citation Information

Patent Citations

  • Microparticle-based enzyme systems for selective removal of target molecules

    US20210213107A1